# Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

> **NCT00312286** · PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 538 (actual)

## Conditions studied

- Papillomavirus Infections

## Interventions

- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B
- **DRUG:** 851B

## Key facts

- **NCT ID:** NCT00312286
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 538 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00312286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00312286, "Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00312286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*